Detalhe da pesquisa
1.
Targeting of Aberrant αvß6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells.
Mol Ther
; 25(1): 259-273, 2017 01 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28129120
2.
Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: identifying a window of therapeutic opportunity?
J Immunol
; 191(9): 4589-98, 2013 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24062490
3.
Targeting of Aberrant αvß6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells.
Mol Ther
; 25(10): 2427, 2017 10 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28958577
4.
Generation of T-cell-receptor-negative CD8αß-positive CAR T cells from T-cell-derived induced pluripotent stem cells.
Nat Biomed Eng
; 6(11): 1284-1297, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35941192
5.
Author Correction: Generation of T-cell-receptor-negative CD8αß-positive CAR T cells from T-cell-derived induced pluripotent stem cells.
Nat Biomed Eng
; 2024 Feb 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38347164
6.
CAR T-cell immunotherapy of MET-expressing malignant mesothelioma.
Oncoimmunology
; 6(12): e1363137, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29209570